Schonfeld Strategic Advisors LLC Cyclacel Pharmaceuticals, Inc. Call Options Transaction History

Schonfeld Strategic Advisors LLC

  • $14.6 Billion
  • Q2 2024

Call Options

1 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q2 2022

Aug 15, 2022
BUY
$6.1 - $7.15 $610,000 - $715,000
100,000 New
100,000 $108,000

About Cyclacel Pharmaceuticals, Inc.

CYCC Quotes by TradingView
  • Ticker CYCC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 12,539,200
  • Market Cap $12.5M
  • Description
  • Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's development programs include fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors, as well as in combin...
More about CYCC
Track This Portfolio

Track Schonfeld Strategic Advisors LLC Portfolio

Follow Schonfeld Strategic Advisors LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Schonfeld Strategic Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Schonfeld Strategic Advisors LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email